28 Oct Complix to Present at CHI’s 7th Annual PEGS Europe Summit, November 5, 2015
Hasselt, October 28, 2015 – Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a novel class of protein therapeutics, announces that its CSO Dr Yvonne McGrath will present a talk entitled “Exploiting the Versatility of Alphabodies to Target the Intrinsic Pro-Survival Protein MCL-1”, at the CHI’s 7th Annual PEGS Europe Summit in Lisbon, Portugal (November 5). The talk will address the discovery and applications of Cell Penetrating Alphabodies (CPABs) active against a target in the intracellular space of cancer cells. Details of the presentation are listed below.
Alphabodies represent a transformative therapeutic development platform with the capacity to address a vast number of disease targets that are currently considered “undruggable” by the main classes of therapeutic drugs like small chemicals or therapeutic antibodies. Cell Penetrating Alphabodies (CPABs) in particular combine small molecule-like attributes, like stability and cell penetration capacity, with typical antibody binding affinity. Thanks to these unique properties CPABs can effectively modulate intracellular protein-protein interactions (PPIs).
It is estimated that there are more than 1000 intracellular disease targets which are known to be involved in important disease processes, but are currently undruggable. The ability to address these targets with a novel therapeutic modality represents a major medical and commercial opportunity.
Upon entering into cells CPABs can cause a disease modifying effect by interacting in a highly specific fashion with particular PPIs. Complix has generated compelling data in its lead CPAB program against the intracellular cancer target MCL-1. MCL-1 is an important regulator of cellular apoptosis and is often over-expressed in cancer cells to prevent them from dying. Complix researchers have demonstrated that MCL-1 targeting CPABs can abolish this effect and induce apoptotic death in the cancer cells.
Details of the presentation are as follow:
Presentation by Dr Yvonne McGrath, CSO of Complix NV
Time: 8:35am GMT, Nov 05 2015
Venue: Epic Sana Lisboa Hotel • Lisbon, Portugal
Complix is a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases.
Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals. Complix´ current R&D efforts are mainly focused on the development of Cell-Penetrating Alphabodies (CPABs) that have the unique capacity to enter tumor cells and selectively modulate intracellular protein-to-protein interactions (PPIs) which play a key role in the initiation and progression of cancer.
Complix has established a strong intellectual property position protecting the Alphabody™ platform and its emerging product portfolio through the filing of multiple broad patent applications. Alphabody-based therapeutics are independent of antibody-based patent claims and offer a unique freedom-to-operate position.
Since its founding in 2008 Complix has raised a total of €26 million in funding (approximately US$ 30 million), including a €12 million B round in June 2013 and a €7 million Series A equity round in 2010.
Dr Yvonne McGrath, CSO
+32 9 261 69 40